AAPL341.32+1.24 (+0.36%) ▲|ABBV266.20+3.00 (+1.14%) ▲|ABT109.56+2.29 (+2.13%) ▲|ACN171.48+6.82 (+4.14%) ▲|ADBE258.88+9.70 (+3.89%) ▲|AMAT451.28-25.18 (-5.28%) ▼|AMD432.93-21.69 (-4.77%) ▼|AMGN395.09+1.99 (+0.51%) ▲|AMT175.97+4.47 (+2.61%) ▲|AMZN227.71-3.15 (-1.36%) ▼|AVGO375.10-5.82 (-1.53%) ▼|AXP333.82-2.81 (-0.83%) ▼|BA212.31-9.26 (-4.18%) ▼|BAC61.89-0.74 (-1.17%) ▼|BKNG200.00+0.69 (+0.35%) ▲|BLK1,101.76+4.21 (+0.38%) ▲|BMY63.65+0.05 (+0.08%) ▲|BNY154.89-1.60 (-1.02%) ▼|BRK-B510.00-2.37 (-0.46%) ▼|C128.77-3.70 (-2.79%) ▼|CAT803.28-37.57 (-4.47%) ▼|CL92.19-0.54 (-0.58%) ▼|CMCSA24.44+0.25 (+1.03%) ▲|COF211.67-0.74 (-0.35%) ▼|COP118.37+4.27 (+3.74%) ▲|COST973.24+6.66 (+0.69%) ▲|CRM183.83+2.33 (+1.28%) ▲|CSCO116.35+0.77 (+0.66%) ▲|CVS108.31-1.03 (-0.94%) ▼|CVX192.55+4.97 (+2.65%) ▲|DE620.23-19.62 (-3.07%) ▼|DHR201.84+2.79 (+1.40%) ▲|DIS98.92+0.03 (+0.03%) ▲|DUK130.08+0.84 (+0.65%) ▲|EMR148.48-3.33 (-2.19%) ▼|FDX310.13-2.51 (-0.80%) ▼|GD393.38+0.19 (+0.05%) ▲|GE356.32-7.28 (-2.00%) ▼|GEV923.17-20.21 (-2.14%) ▼|GILD133.38-0.94 (-0.70%) ▼|GM91.00+0.70 (+0.77%) ▲|GOOG331.19-1.41 (-0.42%) ▼|GOOGL332.34-1.37 (-0.41%) ▼|GS990.92-42.42 (-4.11%) ▼|HD338.33-6.14 (-1.78%) ▼|HON242.76-4.30 (-1.74%) ▼|IBM227.34-0.22 (-0.09%) ▼|INTC83.85-2.45 (-2.84%) ▼|INTU326.39+13.40 (+4.28%) ▲|ISRG356.63-5.17 (-1.43%) ▼|JNJ268.16+1.43 (+0.54%) ▲|JPM350.20-7.12 (-1.99%) ▼|KO90.72+2.45 (+2.78%) ▲|LIN509.84-1.34 (-0.26%) ▼|LLY1,223.45+2.79 (+0.23%) ▲|LMT578.65-2.66 (-0.46%) ▼|LOW216.07-2.18 (-1.00%) ▼|LRCX258.03-11.58 (-4.30%) ▼|MA564.48+1.73 (+0.31%) ▲|MCD271.71-1.31 (-0.48%) ▼|MDLZ65.59+3.11 (+4.98%) ▲|MDT87.80+0.92 (+1.06%) ▲|META586.87-6.54 (-1.10%) ▼|MMM181.61-0.88 (-0.48%) ▼|MO75.43+0.61 (+0.82%) ▲|MRK130.75-1.07 (-0.81%) ▼|MS205.87-5.71 (-2.70%) ▼|MSFT392.47-0.89 (-0.23%) ▼|MU788.34-32.19 (-3.92%) ▼|NEE89.79+0.51 (+0.57%) ▲|NFLX72.02-0.38 (-0.52%) ▼|NKE42.55-0.50 (-1.16%) ▼|NOW113.16+2.54 (+2.30%) ▲|NVDA191.44-5.57 (-2.83%) ▼|ORCL117.86-2.10 (-1.75%) ▼|PEP145.02+2.16 (+1.51%) ▲|PFE25.22-0.03 (-0.12%) ▼|PG145.28-3.61 (-2.42%) ▼|PLTR123.59+0.06 (+0.05%) ▲|PM201.15+0.98 (+0.49%) ▲|QCOM159.03-3.85 (-2.36%) ▼|RTX217.66-0.92 (-0.42%) ▼|SBUX103.59+0.49 (+0.48%) ▲|SCHW105.77-0.20 (-0.19%) ▼|SO97.13+0.35 (+0.36%) ▲|SPG237.22+0.52 (+0.22%) ▲|T24.51-0.15 (-0.61%) ▼|TMO583.43+7.02 (+1.22%) ▲|TMUS181.76-0.63 (-0.35%) ▼|TSLA303.21-4.23 (-1.38%) ▼|TXN271.38-5.69 (-2.05%) ▼|UBER69.78-0.96 (-1.36%) ▼|UNH425.23-3.56 (-0.83%) ▼|UNP292.38-2.07 (-0.70%) ▼|UPS104.47-1.06 (-1.00%) ▼|USB63.56-0.88 (-1.36%) ▼|V369.53+2.94 (+0.80%) ▲|VZ48.16-0.04 (-0.07%) ▼|WFC85.13-1.74 (-2.00%) ▼|WMT113.21+0.11 (+0.10%) ▲|XOM158.57+5.53 (+3.61%) ▲|AAPL341.32+1.24 (+0.36%) ▲|ABBV266.20+3.00 (+1.14%) ▲|ABT109.56+2.29 (+2.13%) ▲|ACN171.48+6.82 (+4.14%) ▲|ADBE258.88+9.70 (+3.89%) ▲|AMAT451.28-25.18 (-5.28%) ▼|AMD432.93-21.69 (-4.77%) ▼|AMGN395.09+1.99 (+0.51%) ▲|AMT175.97+4.47 (+2.61%) ▲|AMZN227.71-3.15 (-1.36%) ▼|AVGO375.10-5.82 (-1.53%) ▼|AXP333.82-2.81 (-0.83%) ▼|BA212.31-9.26 (-4.18%) ▼|BAC61.89-0.74 (-1.17%) ▼|BKNG200.00+0.69 (+0.35%) ▲|BLK1,101.76+4.21 (+0.38%) ▲|BMY63.65+0.05 (+0.08%) ▲|BNY154.89-1.60 (-1.02%) ▼|BRK-B510.00-2.37 (-0.46%) ▼|C128.77-3.70 (-2.79%) ▼|CAT803.28-37.57 (-4.47%) ▼|CL92.19-0.54 (-0.58%) ▼|CMCSA24.44+0.25 (+1.03%) ▲|COF211.67-0.74 (-0.35%) ▼|COP118.37+4.27 (+3.74%) ▲|COST973.24+6.66 (+0.69%) ▲|CRM183.83+2.33 (+1.28%) ▲|CSCO116.35+0.77 (+0.66%) ▲|CVS108.31-1.03 (-0.94%) ▼|CVX192.55+4.97 (+2.65%) ▲|DE620.23-19.62 (-3.07%) ▼|DHR201.84+2.79 (+1.40%) ▲|DIS98.92+0.03 (+0.03%) ▲|DUK130.08+0.84 (+0.65%) ▲|EMR148.48-3.33 (-2.19%) ▼|FDX310.13-2.51 (-0.80%) ▼|GD393.38+0.19 (+0.05%) ▲|GE356.32-7.28 (-2.00%) ▼|GEV923.17-20.21 (-2.14%) ▼|GILD133.38-0.94 (-0.70%) ▼|GM91.00+0.70 (+0.77%) ▲|GOOG331.19-1.41 (-0.42%) ▼|GOOGL332.34-1.37 (-0.41%) ▼|GS990.92-42.42 (-4.11%) ▼|HD338.33-6.14 (-1.78%) ▼|HON242.76-4.30 (-1.74%) ▼|IBM227.34-0.22 (-0.09%) ▼|INTC83.85-2.45 (-2.84%) ▼|INTU326.39+13.40 (+4.28%) ▲|ISRG356.63-5.17 (-1.43%) ▼|JNJ268.16+1.43 (+0.54%) ▲|JPM350.20-7.12 (-1.99%) ▼|KO90.72+2.45 (+2.78%) ▲|LIN509.84-1.34 (-0.26%) ▼|LLY1,223.45+2.79 (+0.23%) ▲|LMT578.65-2.66 (-0.46%) ▼|LOW216.07-2.18 (-1.00%) ▼|LRCX258.03-11.58 (-4.30%) ▼|MA564.48+1.73 (+0.31%) ▲|MCD271.71-1.31 (-0.48%) ▼|MDLZ65.59+3.11 (+4.98%) ▲|MDT87.80+0.92 (+1.06%) ▲|META586.87-6.54 (-1.10%) ▼|MMM181.61-0.88 (-0.48%) ▼|MO75.43+0.61 (+0.82%) ▲|MRK130.75-1.07 (-0.81%) ▼|MS205.87-5.71 (-2.70%) ▼|MSFT392.47-0.89 (-0.23%) ▼|MU788.34-32.19 (-3.92%) ▼|NEE89.79+0.51 (+0.57%) ▲|NFLX72.02-0.38 (-0.52%) ▼|NKE42.55-0.50 (-1.16%) ▼|NOW113.16+2.54 (+2.30%) ▲|NVDA191.44-5.57 (-2.83%) ▼|ORCL117.86-2.10 (-1.75%) ▼|PEP145.02+2.16 (+1.51%) ▲|PFE25.22-0.03 (-0.12%) ▼|PG145.28-3.61 (-2.42%) ▼|PLTR123.59+0.06 (+0.05%) ▲|PM201.15+0.98 (+0.49%) ▲|QCOM159.03-3.85 (-2.36%) ▼|RTX217.66-0.92 (-0.42%) ▼|SBUX103.59+0.49 (+0.48%) ▲|SCHW105.77-0.20 (-0.19%) ▼|SO97.13+0.35 (+0.36%) ▲|SPG237.22+0.52 (+0.22%) ▲|T24.51-0.15 (-0.61%) ▼|TMO583.43+7.02 (+1.22%) ▲|TMUS181.76-0.63 (-0.35%) ▼|TSLA303.21-4.23 (-1.38%) ▼|TXN271.38-5.69 (-2.05%) ▼|UBER69.78-0.96 (-1.36%) ▼|UNH425.23-3.56 (-0.83%) ▼|UNP292.38-2.07 (-0.70%) ▼|UPS104.47-1.06 (-1.00%) ▼|USB63.56-0.88 (-1.36%) ▼|V369.53+2.94 (+0.80%) ▲|VZ48.16-0.04 (-0.07%) ▼|WFC85.13-1.74 (-2.00%) ▼|WMT113.21+0.11 (+0.10%) ▲|XOM158.57+5.53 (+3.61%) ▲|
21.2 C
New York
Wednesday, July 29, 2026

Tag: immune system

newssourceFORcompanyinformationcontent1releasesmarket

Core Axis Introduces Science-Driven Supplement Protocol Developed Specifically for Hashimoto’s Thyroiditis

Cheyenne, Wyoming, July 23, 2026 (GLOBE NEWSWIRE) -- Core Axis, a health brand founded by MC Bio-Logic LLC, announces the upcoming launch of its daily supplement protocol developed with Hashimoto's thyroiditis in mind. Hashimoto's thyroiditis is the autoimmune condition that affects an estimated five million Americans and remains the leading cause of hypothyroidism in the United States. Designed using evidence-based ingredient selection and clinically relevant dosages, the new protocol addresses nutritional factors relevant to individuals with autoimmune thyroid conditions rather than providing general thyroid support. The company is now inviting individuals to join its early access waitlist ahead of the official product launch.

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated Information
Châtillon, France, July 6, 2026

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a...

Nordic Naturals Ultimate Omega Featured in New Erewhon Smoothie by J Balvin

Watsonville, CA, June 26, 2026 (GLOBE NEWSWIRE) -- Nordic Naturals, the #1 selling fish oil brand in the U.S.‡, today announced that its award-winning Ultimate Omega® is a featured ingredient in Erewhon's newly launched, limited-edition “Chimba de Smoothie by J Balvin.”

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChRa or anti-MuSKb antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.3,4

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at...

Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participantsOvarian...

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

Beyond Injections: S-CELL Unveils Breakthrough “Endogenous GLP-1” Formula Powered by Akkermansia P9 Signaling and CoreBiome® Technology

HONG KONG, June 26, 2026 /PRNewswire/ -- S-CELL, a premier innovator in cellular health and anti-aging biotechnology, today announced the launch of its advanced...

JellyFil Discloses 2026 Botanical Ingredient Sourcing, cGMP Manufacturing Standards, Caffeine Content, and Consumer Safety Considerations for Its Premium Gummy Dietary Supplement

JellyFil discloses 2026 gummy supplement ingredient origins, cGMP manufacturing standards, caffeine content, and drug interaction guidance.

Press Release: Sanofi Foundation opens new chapter centered on future generations

Sanofi Foundation opens new chapter centered on future generations

Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility

Optimized capital structure, retiring short-term maturing debt

BienRaíz Launches Vitamin D3 5000 IU Softgels: A High-Potency, Simple Formula for Everyday Wellness

BienRaíz launches Vitamin D3 5000 IU Softgels with sunflower oil. Soy-free & clean-label to support bone, muscle, and immune health.

Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

Sanofi appoints Paulo Fontoura as Global Head of R&D

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsImmune system

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers